3Daughters, Inc.
Clinical development company advancing a frameless, non-hormonal intrauterine device that uses modular magnetic self-assembly and associated flexible insertion/retrieval instrumentation. Platform is designed to enable localized uterine delivery of copper and other locally delivered therapies. Company is in preclinical development, has convened an external scientific advisory board and clinical advisors, has secured government-supported analytical testing for copper release and inflammatory response, completed seed financing and is raising Series A capital to support IND submission and a planned first-in-human Phase 1 trial.
Industries
Nr. of Employees
small (1-50)
3Daughters, Inc.
Mansfield, Massachusetts, United States
Products
Frameless self-assembling magnetic intrauterine device (lead asset)
Non-hormonal, frameless intrauterine device composed of multiple small magnetic modules that self-assemble in situ into a stable configuration and incorporate copper for localized contraceptive effect.
i-Slider
A specialized insertion device for the 3Daughters IUD featuring a flexible and bendable tip that eases the device into the uterus without requiring a tenaculum or uterine sounding.
r-Slider
A magnetic retrieval tool designed to attract and withdraw the three elliptical units of the 3Daughters IUD sequentially in one continuous removal step without strings.
Slider
Patented inserter and retriever system designed to address the pain of IUD insertion and removal.
Frameless self-assembling magnetic intrauterine device (lead asset)
Non-hormonal, frameless intrauterine device composed of multiple small magnetic modules that self-assemble in situ into a stable configuration and incorporate copper for localized contraceptive effect.
i-Slider
A specialized insertion device for the 3Daughters IUD featuring a flexible and bendable tip that eases the device into the uterus without requiring a tenaculum or uterine sounding.
r-Slider
A magnetic retrieval tool designed to attract and withdraw the three elliptical units of the 3Daughters IUD sequentially in one continuous removal step without strings.
Slider
Patented inserter and retriever system designed to address the pain of IUD insertion and removal.
Services
Planning and execution of IND-enabling preclinical studies, regulatory submissions, and early-phase clinical protocol development focused on device safety, insertion performance and procedural endpoints.
Coordination and oversight of analytical and biological preclinical studies conducted at government-supported testing facilities to evaluate release kinetics and biological responses.
Engagement of external scientific advisors and clinical key opinion leaders to inform safety strategy, clinical design and translational decisions.
Planning and execution of IND-enabling preclinical studies, regulatory submissions, and early-phase clinical protocol development focused on device safety, insertion performance and procedural endpoints.
Coordination and oversight of analytical and biological preclinical studies conducted at government-supported testing facilities to evaluate release kinetics and biological responses.
Engagement of external scientific advisors and clinical key opinion leaders to inform safety strategy, clinical design and translational decisions.
Expertise Areas
- Implantable device design and prototyping
- Drug-device combination development and CMC for sustained-release implants
- Nonclinical safety, toxicology and safety pharmacology
- Early-phase clinical trial design and IND preparation
Key Technologies
- Magnetic self-assembly for implantable devices
- Frameless conformable implant geometries
- Flexible insertion and magnetic retrieval instrumentation
- Copper-based local-release systems
News & Updates
National Institute of Child Health and Human Development supported testing at its biological testing facility to evaluate copper release kinetics and inflammatory responses for the frameless magnetic copper IUD in preclinical models.
Company completed an oversubscribed Seed financing round of $4.7 million to support preclinical development toward an IND filing.
Founder moderated a convention session on integrating patient-reported outcomes into clinical development; the session included an FDA divisional director, CRO representation and patient advocacy perspectives.
Relocation to a flexible lab and innovation facility to support growth and access to regional academic and research partners.
Profile piece discussing the company's approach to redesigning the intrauterine device to address insertion pain.
Coverage of corporate relocation and local expansion.
National Institute of Child Health and Human Development supported testing at its biological testing facility to evaluate copper release kinetics and inflammatory responses for the frameless magnetic copper IUD in preclinical models.
Company completed an oversubscribed Seed financing round of $4.7 million to support preclinical development toward an IND filing.
Founder moderated a convention session on integrating patient-reported outcomes into clinical development; the session included an FDA divisional director, CRO representation and patient advocacy perspectives.
Relocation to a flexible lab and innovation facility to support growth and access to regional academic and research partners.
Profile piece discussing the company's approach to redesigning the intrauterine device to address insertion pain.
Coverage of corporate relocation and local expansion.